ATE214276T1 - Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit - Google Patents
Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeitInfo
- Publication number
- ATE214276T1 ATE214276T1 AT95931014T AT95931014T ATE214276T1 AT E214276 T1 ATE214276 T1 AT E214276T1 AT 95931014 T AT95931014 T AT 95931014T AT 95931014 T AT95931014 T AT 95931014T AT E214276 T1 ATE214276 T1 AT E214276T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- alcoholism
- selective serotonin
- treatment
- alcohol dependence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30885994A | 1994-09-19 | 1994-09-19 | |
PCT/US1995/010987 WO1996009047A1 (en) | 1994-09-19 | 1995-09-07 | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE214276T1 true ATE214276T1 (de) | 2002-03-15 |
Family
ID=23195683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95931014T ATE214276T1 (de) | 1994-09-19 | 1995-09-07 | Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit |
Country Status (11)
Country | Link |
---|---|
US (1) | US5958962A (de) |
EP (1) | EP0782445B1 (de) |
AT (1) | ATE214276T1 (de) |
AU (1) | AU3419995A (de) |
CA (1) | CA2197554A1 (de) |
CO (1) | CO4410317A1 (de) |
DE (1) | DE69525847T2 (de) |
DK (1) | DK0782445T3 (de) |
HR (1) | HRP950485A2 (de) |
WO (1) | WO1996009047A1 (de) |
ZA (1) | ZA957891B (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001848A (en) * | 1996-03-25 | 1999-12-14 | The Regents Of The University Of California | Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele |
UA68350C2 (en) * | 1997-07-01 | 2004-08-16 | Pfizer Prod Inc | Dosage forms of encapsulated sertraline |
EP0999830A1 (de) | 1997-07-01 | 2000-05-17 | Pfizer Inc. | Sertraline salze und dozierungsformen für dauerverabreichung enthaltend sertraline |
AU1018801A (en) * | 1999-10-29 | 2001-05-14 | Novo Nordisk A/S | Use of 3,4-substituted piperidines |
SI2517710T1 (sl) * | 2000-02-08 | 2015-07-31 | Euro-Celtique S.A. | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
US7034036B2 (en) * | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
EP1262196A3 (de) * | 2001-05-23 | 2002-12-18 | Pfizer Products Inc. | Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht |
US7034059B2 (en) | 2001-07-02 | 2006-04-25 | Sepracor Inc. | Methods of using norfluoxetine |
JP2005508888A (ja) * | 2001-08-14 | 2005-04-07 | バイオティ セラピーズ コーポレイション | アルコール依存症またはアルコール中毒を治療する方法 |
US20140271788A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
EP2301537A1 (de) | 2002-05-17 | 2011-03-30 | Duke University | Zonisamid zur Behandlung von Fettleibigkeit |
DE10237057A1 (de) * | 2002-08-09 | 2004-03-25 | Grünenthal GmbH | Opioid-Rezeptor-Antagonisten in Pflasterformulierungen |
HUE034290T2 (en) | 2003-04-29 | 2018-02-28 | Orexigen Therapeutics Inc | Preparations containing opioid antagonist and bupropion to affect weight loss |
EP1870096A3 (de) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Zusammensetzungen zur Beeinflussung von Gewichtsverlust |
CA2528508A1 (en) * | 2003-06-06 | 2004-12-16 | Combinatorx Incorporated | System and method for multidimensional evaluation of combinations of compositions |
US7429580B2 (en) | 2004-01-13 | 2008-09-30 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
WO2005107806A1 (en) * | 2004-04-21 | 2005-11-17 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
CA2630624C (en) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
JP2009517393A (ja) * | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | 不安症の治療方法 |
US20070212307A1 (en) * | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
EP2089005B1 (de) | 2006-11-09 | 2010-03-17 | Orexigen Therapeutics, Inc. | Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht |
AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
US9138430B2 (en) * | 2007-12-27 | 2015-09-22 | Mylan Specialty L.P. | Formulation and method for the release of paroxetine in the large intestine |
EP2303025A4 (de) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | Verfahren zur behandlung von eingeweidefettbeschwerden |
US20100168119A1 (en) * | 2008-11-05 | 2010-07-01 | Pharmorx, Inc. | Compositions and methods for minimizing or reducing agonist-induced desensitization |
US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
PL3730132T3 (pl) | 2012-06-06 | 2022-10-10 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
WO2014120936A2 (en) | 2013-01-30 | 2014-08-07 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
AU2154892A (en) * | 1991-05-07 | 1992-12-21 | Dynagen, Inc. | A controlled, sustained release delivery system for treating drug dependency |
US5366990A (en) * | 1991-11-14 | 1994-11-22 | Reid Larry D | Method for treating alcohol abuse and alcoholism |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
-
1995
- 1995-09-07 AT AT95931014T patent/ATE214276T1/de not_active IP Right Cessation
- 1995-09-07 DE DE69525847T patent/DE69525847T2/de not_active Expired - Fee Related
- 1995-09-07 CA CA002197554A patent/CA2197554A1/en not_active Abandoned
- 1995-09-07 EP EP95931014A patent/EP0782445B1/de not_active Expired - Lifetime
- 1995-09-07 WO PCT/US1995/010987 patent/WO1996009047A1/en active IP Right Grant
- 1995-09-07 AU AU34199/95A patent/AU3419995A/en not_active Abandoned
- 1995-09-07 DK DK95931014T patent/DK0782445T3/da active
- 1995-09-19 ZA ZA957891A patent/ZA957891B/xx unknown
- 1995-09-19 CO CO95043013A patent/CO4410317A1/es unknown
- 1995-09-19 HR HR08/308,859A patent/HRP950485A2/hr not_active Application Discontinuation
- 1995-10-13 US US08/542,747 patent/US5958962A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU3419995A (en) | 1996-04-09 |
US5958962A (en) | 1999-09-28 |
EP0782445B1 (de) | 2002-03-13 |
DK0782445T3 (da) | 2002-05-06 |
DE69525847D1 (de) | 2002-04-18 |
CO4410317A1 (es) | 1997-01-09 |
WO1996009047A1 (en) | 1996-03-28 |
CA2197554A1 (en) | 1996-03-28 |
ZA957891B (en) | 1997-03-19 |
HRP950485A2 (en) | 1997-08-31 |
EP0782445A1 (de) | 1997-07-09 |
DE69525847T2 (de) | 2002-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE214276T1 (de) | Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
ATE293989T1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
DE60043308D1 (de) | Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin | |
ATE250932T1 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
DE69616375T2 (de) | Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen | |
DE69720745D1 (de) | Therapeutische kombinationen von rar-antagonisten und rxr-agonisten | |
PT97615A (pt) | Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii | |
EA199800620A1 (ru) | Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды | |
ATE218854T1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase | |
AR002459A1 (es) | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. | |
DE60236496D1 (de) | Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid | |
ATE230993T1 (de) | Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält | |
ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
DE69711078D1 (de) | Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz | |
ES2146249T3 (es) | Composicion farmaceutica para tratar la impotencia que contiene un inhibidor alfa-1 y un inhibidor alfa-2. | |
BR9508406A (pt) | Uso de um composto e método para o tratamento e/ou profilaxia em mamíferos | |
ATE100331T1 (de) | Verfahren zur behandlung von septischem schock. | |
ATE291909T1 (de) | Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene | |
ATE222768T1 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
EA199800535A1 (ru) | Способ лечения боли | |
DE60236927D1 (de) | Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba | |
ATE128871T1 (de) | Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen. | |
DE60017793D1 (de) | Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes | |
ATE236633T1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0782445 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |